WASHINGTON (AP) — President Donald Trump’s acting attorney general on Thursday signed an orderreclassifying state-licensed medical marijuanaas a less-dangerous drug, a major policy shift long sought by advocates who said cannabis should never have been treated like heroin by the federal government.
The order signed by Todd Blanche does not legalize marijuana for medical or recreational use under federal law. But it does change the way it’s regulated, shifting licensed medical marijuana from Schedule I — reserved for drugs without medical use and with high potential for abuse — to the less strictly regulated Schedule III. It also gives licensed medical marijuana operators a major tax break and eases some barriers to researching cannabis.
The Trump administration also said it was jump-starting the process for reclassifying marijuana more broadly, setting a hearing to begin in late June.
Trump told his administration in December to work as quickly as possible toreclassify marijuana. On Saturday, as the Republican president signedan unrelated executive orderabout psychedelics, he seemed to express frustration that it was taking so long.
President Donald Trump waves as he departs after an event for NCAA national champions in the State Dining Room of the White House, Tuesday, April 21, 2026, in Washington. (AP Photo/Alex Brandon)
Blanche said Thursday that the Department of Justice was “delivering on President Trump’s promise” to expand Americans’ access to medical treatment options. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” he said in a statement.
Blanche’s action Iargely legitimizes medical marijuana programs in the 40 states that have adopted them. It sets up an expedited system for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration.
Acting Attorney General Todd Blanche holds a news conference at the Justice Department in Washington, April 7, 2026. (AP Photo/J. Scott Applewhite, File)
It makes clear that cannabis researchers won’t be penalized for obtaining state-licensed marijuana or marijuana-derived products for use in their work, and it grants state-licensed medical marijuana companies a windfall by allowing them, for the first time, to deduct business expenses on their federal taxes.
Any marijuana-derived medicine approved by the Food and Drug Administration is similarly listed in Schedule III, it said.
Source: Drudge Report
